key: cord-0707664-3gc0l58i
authors: Antinori, Andrea; Cicalini, Stefania; Meschi, Silvia; Bordoni, Veronica; Lorenzini, Patrizia; Vergori, Alessandra; Lanini, Simone; De Pascale, Lidya; Matusali, Giulia; Mariotti, Davide; Cozzi Lepri, Alessandro; Gallì, Paola; Pinnetti, Carmela; Gagliardini, Roberta; Mazzotta, Valentina; Mastrorosa, Ilaria; Grisetti, Susanna; Colavita, Francesca; Cimini, Eleonora; Grilli, Elisabetta; Bellagamba, Rita; Lapa, Daniele; Sacchi, Alessandra; Marani, Alessandra; Cerini, Carlo; Candela, Caterina; Fusto, Marisa; Puro, Vincenzo; Castilletti, Concetta; Agrati, Chiara; Girardi, Enrico; Vaia, Francesco
title: Humoral and cellular immune response elicited by mRNA vaccination against SARS-CoV-2 in people living with HIV (PLWH) receiving antiretroviral therapy (ART) according with current CD4 T-lymphocyte count
date: 2022-04-02
journal: Clin Infect Dis
DOI: 10.1093/cid/ciac238
sha: c06a7dcf29b300758d021856eb7f0e1bd35b4e10
doc_id: 707664
cord_uid: 3gc0l58i

BACKGROUND: Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited. Aim of the study was to investigate immunogenicity according to current CD4 T-cell count. METHODS: PLWH on ART attending a SARS-CoV-2 vaccination program, were included in a prospective immunogenicity evaluation after receiving BNT162b2 or mRNA-1273. Participants were stratified by current CD4 T-cell count (poor CD4 recovery, PCDR: <200/mm (3); intermediate CD4 recovery, ICDR: 200-500/mm (3) high CD4 recovery, HCDR: >500/mm (3)). RBD-binding IgG, SARS-CoV-2 neutralizing antibodies (nAbs) and IFN-γ release were measured. As control group, HIV-negative healthcare workers (HCWs) were used. FINDINGS: Among 166 PLWH after 1 month from the second dose, detectable RBD-binding IgG were elicited in 86.7% of PCDR, 100% of ICDR, 98.7% of HCDR, and a neutralizing titre ≥1:10 elicited in 70.0%, 88.2% and 93.1%, respectively. Compared to HCDR, all immune response parameters were significantly lower in PCDR. After adjusting for confounders, current CD4 T-cell <200/mm (3) significantly predicted a poor magnitude of anti-RDB, nAbs and IFN-γ response. As compared with HCWs, PCDR elicited a consistently reduced immunogenicity for all parameters, ICDR only a reduced RBD-binding antibody response, whereas HCDR elicited a comparable immune response for all parameters. CONCLUSION: Humoral and cell-mediated immune response against SARS-CoV-2 were elicited in most of PLWH, albeit significantly poorer in those with CD4 T-cell <200/mm (3) versus those with >500 cell/mm (3) and HIV-negative controls. A decreased RBD-binding antibody response than HCWs was also observed in PLWH with CD4 T-cell 200-500/mm (3), whereas immune response elicited in PLWH with a CD4 T-cell >500/mm (3) was comparable to HIV-negative population.

M a n u s c r i p t

Effective vaccination strategy currently represents the main control measure of pandemic 1 , particularly in highly vulnerable people at high risk of severe COVID-19 2 .

In people living with HIV (PLWH), despite the early antiretroviral therapy (ART) beneficial effects 3 , they may persistently experience a chronic immune dysregulation 4 , causing a not fully restored immune health 5 .

Observational studies suggested that COVID-19 may have a worse prognosis in PLWH compared to HIVnegative population, with an increased risk of mortality [6] [7] . Recent data suggested that a higher risk of severe COVID-19 in PLWH may be associated with poor neutralising antibody (nAbs) titres and this might reflect a diminished antibody response to SARS-CoV-2 natural infection 8 . These data are consistent with the observation that HIV infection may favor a poor serological response to vaccines for viral agents, such as influenza 9 or hepatitis B 10 .

At present, few data have been published on the immunogenicity of SARS-CoV-2 vaccination in PLWH.

Preliminary data in PLWH from a single-arm open-label study from a large, controlled, phase 2/3 randomized trial in UK, showed that ChAdOx1-nCoV-19 vaccine, given as prime-boost dosing 4-6 weeks apart, was safe and produced consistent immune responses in PLWH on ART and with CD4 counts above 350 cells/mm 3 11 .

Similarly, the interim results from a randomized, double-blind, placebo-controlled phase 1b/2 trial on the safety and immunogenicity of the same adenovirus-vectored vaccine in South Africa, showed comparable safety and immunogenicity between PLWH, with a median count of 695 cell/mm 3 , and HIV-negative people 12 .

Three observational studies were published on mRNA vaccines in PLWH. In the first study, 98% of HIV-infected individuals enrolled in a prospective evaluation of BNT162b2 vaccine with a mean CD4 count of 700 cell/ mm 3 showed a RBD-binding IgG response detectable at a median of 18 days after the second dose 13 . In a small size prospective study, on PLWHs with a median of 913 CD4 T-cells/mm 3 receiving BNT162b2, a robust humoral and cellular immune response, comparable to that observed in healthy donors, was observed 14 . Finally, in another small size prospective study, HIV-infected individuals receiving BNT162b2 or mRNA-1273, of whom 86% with a CD4 count >200 cell/mm 3 , developed high titers of anti-RBD antibodies 15 . Nonetheless, in these studies, the information about the immunogenicity of SARS-CoV-2 vaccination in PLWH with low current CD4

T-cell count is lacking, and the value of this marker in predicting vaccine response in HIV-infected people has

not been yet estimated.

Aim of the present study was to evaluate the immunogenicity of a SARS-CoV-2 vaccination with a mRNA Here we present results on immunogenicity (humoral, neutralizing and cell-mediated response) at T1 and T2 of follow-up. The study population consisted of PLWH who completed the 2-dose schedule with BNT162b2 or mRNA-1273 vaccines up to July 20, 2021 and consecutively enrolled at the immunogenicity sub-study.

Individuals with a SARS-CoV-2 infection diagnosis, defined by a RT-PCR positive on the nasopharyngeal swab, or positivity to anti-N and/or to anti-Spike receptor-binding domain (anti-S/RBD) antibodies at T0, or to anti-N at T1 or T2, were excluded for the present analysis. An unmatched control group of health care workers (HCWs), vaccinated with BNT162b2 who underwent the same schedule of blood sample collection, enrolled in another surveillance study 16 , were included as external controls.

Two commercial chemiluminescence microparticle antibody assays (CMIA), the SARS-CoV-2 specific anti-N, Ab NIBSC code 20/130) was used as reference in MNA.

We studied IFN-γ and IL-2 production in response to Spike stimulation as a surrogate of specific T-cell function.

Briefly, whole blood was stimulated in vitro at 37°C (5% CO2) with a pool of peptides covering the sequence of 

PLWH included in the present analysis were stratified into three groups according to the degree of immune recovery: 1) patients with current CD4 T-cell <200/mm 3 (poor CD4 recovery, PCDR); 2) patients with current

CD4 T-cell between 200 and 500 cell/mm 3 

N=166 PLWH were included in the analysis (PCDR=32; ICDR=56; HCDR=78). The main characteristics of HIVinfected participants according to current CD4 T cell count at vaccination were reported in 

We first compared RBD-binding IgG responses by gender and we found no evidence for an association. Figure S2a) . M a n u s c r i p t 8

We first compared T-cell responses by gender and we found no evidence for an association. Figure S2b) .

In PLWHs, a significant correlation between CD4 T cell/mm 3 and magnitude of RBD-binding IgG (Figure 6a ), nAbs ( Figure 6b ) and IFN-γ release (Figure 6c ) was observed by simple linear regression. Having magnitude of RBD-binding IgG production, nAbs titre and IFN-γ release as dependent covariates, current CD4 count <200 cell/mm 3 was associated with a significantly lower magnitude of immune response, after adjusting for the main identified confounders (age, years of HIV infection, CD4 nadir, HIV-RNA <50 vs >50 copies/mL, type of mRNA vaccine and previous or current malignancy) ( Table 3 ). CD4/CD8 ratio was associated only with increasing magnitude of RBD-binding IgG production after multivariable adjustment ( Table 3) .

Compared to HCWs, the proportion of a detectable RBD-binding IgG response after 1 month from second dose, was lower in PCDR (p<0.001), but comparable in ICDR (p=1.0) and in HCDR (p=0.313) ( Table 2) A c c e p t e d M a n u s c r i p t 9 stimulation was lower in PCDR (p<0.001), in ICDR (p=0.020), but not in HCDR (p=0.528) (Figure 4a ), and the median (IQR) value of IL-2 release after stimulation lower in PCDR (p=0.024) but not in ICDR (p=1.000) or in HCDR (p=0.932) (Figure 4b ). Having HCWs as reference, after adjustment for gender and age by multivariable linear regression, a significant association between PCDR and reduction of magnitude of immune response was found for all three parameters (MNA p<0.001; RBD-binding IgG p<0.001; IFN-γ p<0.001). ICDR was associated only with a significant reduction of RBD-binding antibodies, whereas no significant association, after multivariable adjustment, was observed for HCDR (Table 4) .

According to these findings, SARS-CoV-2 vaccination with a mRNA vaccine induced a robust humoral and cell- A low CD4/CD8 ratio was also suggested as factor associated with increased innate and adaptive immune activation, immune-senescent phenotype 20 and also to a poor magnitude of SARS-CoV-2-specific responses 21 .

In our analysis, CD4/CD8 ratio was independently associated only with RBD-binding production after vaccination, but not to neutralizing or cell-mediated response, although we cannot exclude a residual effect.

Our data highlighted that PLWH seem to display a better immune response after SARS-CoV-2 vaccination than observed for other immunosuppressed populations as solid organ transplant recipients 22 : 35% of renal A c c e p t e d M a n u s c r i p t 10 transplant recipients developed nAbs after BNT162b2 vaccination 23 , and similar results were observed in those receiving rituximab 24 ,poorer rates than 70% observed in PLWH with very low latest CD4 T-cell count. A reasonable explanation of this discrepancy may be due to the different mechanisms of immunosuppression in the two populations. Transplant recipients or patients receiving anti-CD20 therapy experience a strong active pharmacological immunosuppression due to the ongoing treatment; in contrast, the effective ART able to suppress HIV replication can allow a partial restoration of functional immune response also in patients with a still low CD4 T-cell count.

Main limitation of our study was the observational, not randomized nature of the design, lacking of a matched HIV-negative control group. However, the comparisons with HCWs were controlled for gender and age. M a n u s c r i p t 21 

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Development and deployment of COVID-19 vaccines for those most vulnerable

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

HIV-associated chronic immune activation

The end of AIDS: HIV infection as a chronic disease

Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study

Epub ahead of print

HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform

SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study

Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIVinfected individuals

Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

ChAdOx1 nCoV-19 (AZD1222) Vaccine in People Living With and Without HIV

Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine

SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus. Viruses

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality

Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies

Epub ahead of print

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigatorinitiated, single-centre, open-label study

Abbreviations: PCDR, poor CD4 recovery; ICDR, intermediate CD4 recovery; HCDR, high CD4 recovery

Abbreviations: PCDR, poor CD4 recovery

ICDR, intermediate CD4 recovery

P=0.014; PCDR vs HCDR, P=0.021; ICDR vs HCDR, P=1.0. Comparisons of PLWHs with HCWs by Fisher's exact test: PCDR vs HCWs, P <0.001

Comparisons between HIV groups by Kruskal-Wallis test P<0.001; by Dunn's test with Bonferroni adjustment for multiple comparisons: PCDR vs ICDR, P=0.029; PCDR vs HCDR, P<0.001; ICDR vs HCDR, p=0.184. Comparisons of PLWHs with HCWs by Kruskal-Wallis test p<0.001; by Dunn's test with Bonferroni adjustment: PCDR vs HCWs

PCDR vs HCDR, p=0.002; ICDR vs HCDR, p=0.356. Comparisons of PLWHs with HCWs by Fisher's exact test: PCDR vs HCWs

§ Comparisons between HIV groups by Kruskal-Wallis test p<0.001; by Dunn's test with Bonferroni adjustment for multiple comparisons: PCDR vs ICDR, p=0.150; PCDR vs HCDR, p=0.001; ICDR vs HCDR, p=0.239. Comparisons of PLWHs with HCWs by Kruskal-Wallis test p<0.001; by Dunn's test with Bonferroni adjustment: PCDR vs HCWs

A c c e p t e d M a n u s c r i p t 13 A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t